Aim: To evaluate the prognostic value of circulating VE-catherin for cumulative survival in patients with regression of multiple myeloma. Methods: Eighty nine out subjects with regression of multiple myeloma were enrolled in the study. Observation period was up to 12 months. Blood samples for biomarkers measurements were collected. ELISA method for measurements of circulating level of VE-catherin was used. Results: Ninety two cumulative clinical events occurred in 36 patients (40,5%) within the follow-up, with their distribution being as follows: 8 cardiovascular deaths, 46 cardiac arrhythmias, 8 cardiac ischemic events, 2 strokes, 8 chronic heart failures and 22 hospital admissions for cardiovascular reasons. Medians of circulating levels of N-terminal pro-brain natriuretic protein (NT-pro-BNP) in free-events subject cohort and subjects cohort with cardiovascular events were 5,68 ng/ml (95% confidence interval [CI] = 1,31-11,59 ng/ml) and 23.8 ng/ml (95% CI = 5,11-41,84 ng/ml) (р=0.004). Medians of circulating levels of VEcatherin in free-events subject cohort and subjects cohort with cardiovascular events were 0,41 ng/ml (95% confidence interval [CI] = 0,30-0,52 ng/ml) and 1,51 ng/ml (95% CI = 1,21-1,82 ng/ml) (р<0.001). In multivariate logistic regression circulating VE-catherin independently predicted cumulative cardiovascular events (odds ratio [OR] = 1,12; 95% CI = 1,03-1,15; р = 0.001) within 12 months of observation period. However, NT-pro-BNP and Е/Em remained statistically significant 126 Borys B. Samura predictors for cumulative cardiovascular events (OR = 1.04; 95% CI 1.02-1.11; P < 0.05 and OR = 1.05; 95% CI = 1.03 -1.09; P<0.02), whereas T2DM, hypertension, obesity, and LVEF did not. Conclusion: Among patients with documented multiple myeloma in remission increased circulating VE-catherin associates with increased cumulative cardiovascular events.
Introduction
Endothelial damage and perivascular plasma cells infiltrates are vital in the development of multiple myeloma. Recent studies have found that endothelial dysfunction might be result in multiple myeloma progression and adverse effects of drug implementation [4] . On the other hand, there is a direct correlation between microvessel density in multiple myeloma and parameters of disease progression [11] .
Serum levels of natriuretic peptides are important, not just as indicators of numerous cardiovascular deficiencies but also as markers of their severity. Nterminal pro-brain natriuretic protein (NT-proBNP) demonstrates a high sensitivity for detecting patients with risk of sudden death, the specificity of this neurohormone is decreased. A diverse analysis between mortality and levels of NT-proBNP demonstrated a positive linear correlation between the risk of death and NTproBNP level [1, 9] .
With regard to the prognostic value of NT-pro-BNP for chronic heart failure, the Valsartan Heart Failure Trial demonstrated the positive nature of advanced heart failure. Moreover, NT-proBNP concentrations appeared significantly increased in patients with dilated cardiomyopathy and cardiovascular disease [10] .
Endothelial cells participate in inflammatory events leading to atherogenesis by regulating endothelial cell permeability via the expression Vascular endothelialcadherin (VE-cadherin) on their surface. VE-cadherin is cell adhesion molecules localized at the endothelial junction, which plays critical roles in angiogenesis, neovascularization, neoplasm development, stem cells mobbing, and endothelial integrity [2, 8] . Indeed, VE-cadherin chiefly organizes the opening and closing of the endothelial barrier [3] . It has found that VE-cadherin as a transmembrane protein probably modulates intensity of angiogenesis in lymphoproliferative diseases and may be useful in prognosis of response to treatment [7, 12, 13] . However, the predictive role of VE-cadherin as a marker of cardiovascular events in patients in regression of lymphoproliferative diseases is not still clear. The aim of the study to evaluate the prognostic value of circulating VE-catherin for cumulative survival in asymptomatic coronary artery disease patients with regression of lymphoproliferative diseases.
Design and Methods
Eighty nine out subjects with multiple myeloma in full or partial remission were enrolled in the study. All subjects gave their written informed consent to participation in the study. Diagnosis and staging of multiple myeloma were defined by current clinical practice guidelines [5] . To be achieving regression chemotherapy was used accordingly contemporary clinical guidelines. All subjects were at regression stage at baseline.
Echocardiography in B-mode was performed accordingly to Recommendation of American Society of Echocardiography on the scanner "MyLab 50" (Italy) using a transducer with a frequency of 2.5-3.5 MHz. Enddiastolic and end-systolic LV volumes were obtained using a two-dimensional reference sector according to Simpson's method, and LV ejection fraction (LVEF) was calculated by accordingly conventional methods [6] .
All blood samples were collected after fasting in cooling vacutaner and after that it was immediately centrifugated (4°C for 6.000 × 15 min). After centrifugation serum was blind coded and stored at -35° until used. NT-pro-BNP and VE-cadherin levels were measured by ELISA technique. Human VE-cadherin Quantikine ELISA Kit (R&G, United Kingdom) was used for examination. All determinations were done by duplicating. The mean intra-assay coefficients of variation were <10% of all cases.
Fasting plasma glucose (FPG) was quantified by the glucose oxidase procedure; HbA1c was measured by ion-exchange high-performance liquid chromatography (HPLC; Bio-Rad, Hercules, CA, USA).
Concentrations of total cholesterol (TC) and high density lipoprotein (HDL) cholesterol were determined by a Dimension Clinical Chemistry System (Dade Behring Inc, Newark, NJ). Low density lipoprotein (LDL) cholesterol was calculated by using the formula of Friedewald W.T., Levy R.I., Fredrickson D.S. (1972) . All measurements and blood sample for VE-cadherin, glucose, creatinin, glycated hemoglobin (HbA1c), TC, LDL-C, HDC-C were collected at the same visit.
Clinical Events: Screening and Diagnostics Clinical interviews were carried out every month for three years after baseline. The following are the clinical events verified: newly diagnosed strokes or TIAs; death for any reasons and sudden cardiac death; coronary ischemic events (myocardial infarction, unstable angina) that needed hospital admission for cardiovascular reasons, new-onset chronic heart failure. Newly diagnosed strokes were confirmed with CT. All clinical events were presented as cumulative.
Statistical Analysis
All statistical analyses were performed in SPSS for Windows v. 17.0 (SPSS Inc., Chicago, IL, USA). All values were given as mean and 95% CI or median and percentiles. An independent group t-test was used for comparisons for all interval parameters meeting the criteria of normality and homogeneity of variance. For interval parameters not meeting these criteria, the non-paramentric Mann-Whitney test was used to make comparisons between the groups. Comparisons of categorical variables between the groups were performed using the Chi2 test, and the Fisher exact test. VE-cadherin concentration was normally distributed and it was no positively skewed. However, the data were not transformed. The potential factors (age; sex, smoking, systolic and diastolic BP, VE-cadherin, NT-proBNP, fasting plasma glucose, hypercholesterolemia, TC, LDL cholesterol, creatinin level, HbA1c) that may be associated with cardiovascular events was identified first by the univariate analysis (ANOVA), then multivariate logistic regression analyses were used to identify the predict factors. A calculated difference of P<0.05 was considered significant.
Results
Ninety two cumulative clinical events occurred in 36 patients (40,5%) within the follow-up, with their distribution being as follows: 8 cardiovascular deaths, 46 cardiac arrhythmias, 8 cardiac ischemic events, 2 strokes, 8 chronic heart failures and 22 hospital admissions for cardiovascular reasons.
General characteristics of study patients are presented in table 1. Significant differences between the both cohorts of patients for demographics (age, sex), conventional risk factor (smoking, arterial hypertension, dyslipidemia, T2DM, BMI, obesity and overweight), biochemical (creatinine, total cholesterol, LDL cholesterol, and HDL cholesterol, fasting blood glucose) and some hemodynamic parameters (mean systolic and diastolic BP, heart rate, LV EF, Е/Аm, and Е/Em) were not found. On the other hand, there was significant difference between both cohorts in incidences of heart failure (P<0.001). Therefore, circulating level of NTpro-BNP was much higher in free-events subject cohort when compared with subjects cohort with cardiovascular events occurred.
All hypertensive patients were treated according to current clinical guidelines with diet, lifestyle modification and drug therapy that included ACE inhibitors / ARBs, aspirin or other antiagregants, statins. Metformin was prescribed in 1 (1.9%) and 3 (8.3%) T2DM patients in both cohorts, in other cases diet and life-style modification were recommended only. Because incidences of heart failure was seen significantly often in subjects cohort with cardiovascular events in comparison with free-events subject cohort, however, ACEI / ARAs, mineralcorticoid receptors antagonists, and diuretics have been used increasingly.
Medians of circulating levels of VE-catherin in free-events subject cohort and subjects cohort with cardiovascular events were 0,41 ng/ml (95% confidence interval [CI] = 0,30-0,52 ng/ml) and 1,51 ng/ml (95% CI = 1,21-1,82 ng/ml) (р<0.001). Medians of circulating levels of NT-pro-BNP in free-events subject cohort and subjects cohort with cardiovascular events were 5,68 ng/ml (95% confidence interval [CI] = 1,31-11,59 ng/ml) and 23.8 ng/ml (95% CI = 5,11-41,84 ng/ml) (р=0.004). The data suggested that VE-catherin plasma levels were directly related to NT-pro-BNP (r = 0.39, P = 0.047).
No significant association between the levels of circulating VE-catherin with Е/Аm, Е/Em, LVEF, T2DM, fasting plasma glucose, HbA1c, TC, age, smoking, mean systolic and diastolic BP, and medications for both cohorts of the patients was found.
Univariate and multivariate logistic regressions were used to assess whether biomarker was able to better discriminate between two patient cohorts. In the univariate logistic regression analysis, the main factors independently related with cumulative cardiovascular events were VE-catherin, NT-pro-BNP, Е/Em, LVEF, T2DM, hypertension, and obesity.
In multivariate logistic regression circulating VE-catherin independently predicted cumulative cardiovascular events (odds ratio [OR] = 1,12; 95% CI = 1,03-1,15; р = 0.001) within 12 months of observation period. However, NT-pro-BNP and Е/Em remained statistically significant predictors for cumulative cardiovascular events (OR = 1.04; 95% CI 1.02-1.11; P < 0.05 and OR = 1.05; 95% CI = 1.03 -1.09; P<0.02), whereas T2DM, hypertension, obesity, and LVEF did not. Note: * -statistically differences between parameters in the two groups (P<0.05); CI -confidence interval, T2DM -type two diabetes mellitus, GFR -Glomerular filtration rate, HDL-C -high-density lipoprotein cholesterol, LDL-C -Low-density lipoprotein cholesterol, BP -blood pressure, BMI -Body mass index, BNP -brain natriuretic peptide, LVEF -Left ventricular ejection fraction, U -unit, Em -early diastolic myocardial velocity, Аm -late diastolic myocardial velocity, E -peak velocity of early diastolic left ventricular filling, ACEI -angiotensin-converting enzyme inhibitor, ARAs -angiotensin-2 receptors antagonists.
Discussion
Despite the presence of guidelines related to multiple myeloma there are still gaps between best evidence as described in guidelines and quality of care in daily practice. Little is known about factors that affect this discrepancy. It is postulated that a part of the patients with documented lymphoproliferative diseases might be identified at high cardiovascular risk. The conventional treatments used in most cases and coexisting conventional risks factors contribute worsening endothelial function and destroying endothelial layer. In this regard, biological markers that devoted severity of endothelial dysfunction look promising. We found that raised level of VE-catherin associated with a greater risk of cardiovascular events in patients with regression of multiple myeloma. Moreover, predictive value of VEcatherin was superior when compared with LVEF and NT-pro-BNP. While natriuretic peptides are strong prognostic indicators in heart failure, and possibly superior to traditional prognostic factors, the levels of NT-pro-BNP must be interpreted according to the clinical picture [9] . Looking for novel biomarkers are required to be improving reclassification of the risk in cumulative cardiovascular events over a clinical prediction model. Further research is necessary to understand the prognostic value of VE-catherin in patients with multiple myeloma.
In conclusion, among patients with documented multiple myeloma in remission increased circulating VE-catherin associates with increased cumulative cardiovascular events.
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Limitations of the study. This study has some limitations. We believed that a greater cohort would be desirable to improve the power of the study. We also relied on clinical data to rule out infection and other inflammatory diseases before sampling, but we couldn't exclude that some patients had unrecognized the conditions responsible for the elevated VE catherin levels observed.
